ESR1 and breast carcinoma: For HR+ metastatic breast cancer, the NeoPACT trial evaluated pembrolizumab in combination with chemotherapy in patients with HR+ breast cancer, albeit with weak HR positivity (1–10% of cells expressing estrogen receptor).